

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 October 2024 (10.10.2024)



(10) International Publication Number
WO 2024/207067 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61K 39/00* (2006.01)
A61K 31/454 (2006.01) *A61P 35/00* (2006.01)
A61K 31/573 (2006.01) *C07K 16/30* (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/AU2024/050320

(22) International Filing Date:

04 April 2024 (04.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023900983 04 April 2023 (04.04.2023) AU

(71) Applicant: **HAEMALOGIX LTD** [AU/AU]; Suite 204, 80 William Street, Woolloomooloo, New South Wales 2011 (AU).

(72) Inventors: **DUNN, Rosanne**; c/o HaemaLogiX Ltd, Suite 204, 80 William Street, Woolloomooloo, New South Wales 2011 (AU). **HUSSEIN, Mohamad**; c/o HaemaLogiX Ltd, Suite 204, 80 William Street, Woolloomooloo, New South Wales 2011 (AU). **SPENCER, Andrew**; c/o HaemaLogiX Ltd, Suite 204, 80 William Street, Woolloomooloo, New South Wales 2011 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 11, Waterfront Place, 1 Eagle Street, Brisbane, Queensland 4000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: A DOSING REGIMEN

(57) Abstract: The present disclosure relates to combination dosing regimen comprising an anti-KMA antibody, an IMiD/CELMoD and a steroid. Such combinations may be used for the treatment of multiple myeloma.

WO 2024/207067 A1